Stereotactic body radiotherapy to the lung primary lesion improves the survival of patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: A real-world study

被引：0

作者：

Wei, H. ^{[1
]}

Zhou, X. ^{[1
]}

Yang, H. ^{[1
]}

Gong, Y-L. ^{[2
,3
]}

Wang, J. ^{[1
]}

Xu, Y. ^{[1
]}

Zhou, L. ^{[1
]}

Xue, J. ^{[1
]}

Zou, B. ^{[4
]}

Zhang, Y. ^{[1
]}

Zhu, J. ^{[1
]}

Peng, F. ^{[1
]}

Huang, M. ^{[1
]}

Lu, Y. ^{[1
]}

Liu, Y. ^{[1
]}

机构：

[1] Sichuan Univ, Dept Thorac Oncol, West China Hosp, Chengdu, Peoples R China

[2] Sichuan Univ, Dept Thorac Oncol, Ctr Canc, West China Hosp, Chengdu, Peoples R China

[3] Sichuan Univ, West China Hosp, Ctr Canc, State Key Lab Biotherapy, Chengdu, Peoples R China

[4] Sichuan Univ, Sch Med, West China Hosp, Dept Thorac Oncol, Chengdu, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1832

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1227P

引用

页码：S973 / S973

页数：1

共 50 条

[41] Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR plus NSCLC Patients: The Updated Results
Fang, S.
Xu, T.
Zhao, X.
Liu, N.
Wang, X.
Cheng, W.
Fang, H.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S671
[42] Comparison of first and third generation EGFR-TKIs for the treatment of advanced non-small cell lung cancer: A real-world study
Shah, Maitri
Shah, Kashvi
Dave, Hetvi
Khadela, Avinash
Desai, Chirag
Shah, Sanket
Shah, Gaurang
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025,
[43] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
Shun Lu
Jin-Yuan Shih
Tae-Won Jang
Chong-Kin Liam
Yongfeng Yu
Advances in Therapy, 2021, 38 : 2038 - 2053
[44] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
Lu, Shun
Shih, Jin-Yuan
Jang, Tae-Won
Liam, Chong-Kin
Yu, Yongfeng
ADVANCES IN THERAPY, 2021, 38 (05) : 2038 - 2053
[45] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
Aguilar-Serra, J.
Gimeno-Ballester, V
Pastor-Clerigues, A.
Milara, J.
Trigo-Vicente, C.
Cortijo, J.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
[46] Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
Wang, Yujia
Wu, Guoyu
Li, Ru
Luo, Yingzhe
Huang, Xingmei
He, Lifang
Zhong, Huihui
Xiong, Shaoquan
FRONTIERS IN PUBLIC HEALTH, 2021, 9
[47] Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Gwo-Fuang Ho
Chee-Shee Chai
Adlinda Alip
Mohd Ibrahim A. Wahid
Matin Mellor Abdullah
Yoke-Ching Foo
Soon-Hin How
Adel Zaatar
Kai-Seng Lam
Kin-Wah Leong
John-Seng-Hooi Low
Mastura Md Yusof
Erica Chai-Yong Lee
Yok-Yong Toh
Chong-Kin Liam
BMC Cancer, 19
[48] Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Ho, Gwo-Fuang
Chai, Chee-Shee
Alip, Adlinda
Wahid, Mohd Ibrahim A.
Abdullah, Matin Mellor
Foo, Yoke-Ching
How, Soon-Hin
Zaatar, Adel
Lam, Kai-Seng
Leong, Kin-Wah
Low, John-Seng-Hooi
Yusof, Mastura Md
Lee, Erica Chai-Yong
Toh, Yok-Yong
Liam, Chong-Kin
BMC CANCER, 2019, 19 (01)
[49] The progression-free survival of the first-line EGFR-TKI is a strong prognosticator of the second-line osimertinib in non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation: A real-world study
Tang, X.
Qian, W-L.
Pang, T.
Gong, Y-L.
Yang, Z-G.
ANNALS OF ONCOLOGY, 2021, 32 : S972 - S972
[50] Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment
Yang Ni
Xin Ye
Xia Yang
Guanghui Huang
Wenhong Li
Jiao Wang
Xiaoying Han
Zhigang Wei
Min Meng
Journal of Cancer Research and Clinical Oncology, 2020, 146 : 197 - 203

← 1 2 3 4 5 →